34 results on '"van Glabbeke, Martine"'
Search Results
2. Achievements of the EORTC Soft Tissue and Bone Sarcoma Group
3. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
4. Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
5. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
6. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
7. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
8. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin’s lymphoma
9. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
10. Late Non-Neoplastic Events in Patients with Aggressive Non-Hodgkin's Lymphoma in Four Randomized European Organisation for Research and Treatment of Cancer Trials
11. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
12. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
13. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
14. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis
15. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
16. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC)
17. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC
18. Age has no impact on acute and late toxicity of curative thoracic radiotherapy
19. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
20. Phase II studies on prostate cancer
21. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844
22. The eortc randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: Long-term results and side effects
23. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects
24. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors
25. Phase II trial of Menogaril in advanced malignant melanoma. An EORTC trial
26. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma
27. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer
28. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group
29. Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas A pilot feasibility study of the Radiotherapy Group of the EORTC
30. Phase II trial of triglycidylurazol (TGU) in advanced malignant melanoma
31. Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent — A phase II study of the EORTC early clinical trials group
32. Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy
33. Reproducibility and prognostic value of different non-Hodgkin's lymphoma classifications: Study based on the clinicopathologic relations found in the EORTC trial (20751)
34. Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.